Blog Archives

Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities

Enzyvant Newsrooom | April 2022

Reading Time: 4 minutes

Sumitovant and Enzyvant Appoint Bill Symonds, CEO of Altavant Sciences, as Interim Chief Executive Officer of Enzyvant

Enzyvant Newsrooom | March 2022

Reading Time: 3 minutes

Enzyvant Appoints Johanna Rossell as Chief Commercial Officer

Enzyvant Newsrooom | January 2022

Reading Time: 5 minutes

Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia

Enzyvant Newsrooom | October 2021

Reading Time: 6 minutes

Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia

Enzyvant Newsrooom | August 2021

Reading Time: 6 minutes

Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)

Enzyvant Newsrooom | August 2021

Reading Time: 5 minutes

Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest

Enzyvant Newsrooom | May 2021

Reading Time: 5 minutes

ENZYVANT Resubmits Biologics Licensing Application (BLA) to FDA for RVT-802 for Pediatric Congenital Athymia

Enzyvant Newsrooom | April 2021

Reading Time: 3 minutes

Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant Sciences

Enzyvant Newsrooom | December 2019

Reading Time: 3 minutes

Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance

Enzyvant Newsrooom | November 2019

Reading Time: 5 minutes

Enzyvant Appoints Jeb Ledell as Chief Operating Officer

Enzyvant Newsrooom | October 2019

Reading Time: 2 minutes

Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia

Enzyvant Newsrooom | June 2019

Reading Time: 5 minutes

Enzyvant’s Investigational Regenerative Treatment (RVT-802) for Congenital Athymia to be Discussed in Symposium, Platform Presentation and Poster Session at Clinical Immunology Society Meeting

Enzyvant Newsrooom | April 2019

Reading Time: 3 minutes

Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer

Enzyvant Newsrooom | February 2019

Reading Time: 2 minutes

Enzyvant Announces Initiation of RVT-802 Rolling BLA Submission for the Treatment of Complete DiGeorge Anomaly

Enzyvant Newsrooom | July 2018

Reading Time: 3 minutes